Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics Inc. (ADMA) is a commercial-stage biopharmaceutical company advancing plasma-derived therapies for immune deficiencies and infectious diseases. This dedicated news hub provides verified updates on corporate developments, regulatory milestones, and clinical progress.
Investors and healthcare professionals will discover timely coverage of earnings announcements, FDA decisions, manufacturing innovations, and strategic partnerships. Our curated selection emphasizes ADMA’s operational achievements in plasma collection, biomanufacturing excellence, and therapeutic pipeline advancements.
Key updates include product authorization progress, financial disclosures, patent developments, and peer-reviewed research findings. All content undergoes rigorous verification to ensure accuracy for investment and industry analysis.
Bookmark this page for direct access to ADMA’s official communications and expertly contextualized news. Maintain awareness of critical developments impacting this innovative biologics manufacturer through Stock Titan’s trusted reporting.
ADMA Biologics reported a 90% year-over-year revenue growth in the fourth quarter of 2022, totaling $50 million. This growth primarily stems from increased sales of their intravenous immune globulin products. The company achieved a gross profit of $14 million, reflecting a dramatic improvement from $3.5 million in the same quarter last year.
For 2023, ADMA anticipates revenues exceeding $210 million and aims for its first positive EBITDA by the second half of the year. The company has identified new growth opportunities and plans to expand ASCENIV production capacity, which should enhance margins significantly.
ADMA Biologics will report its fourth quarter and full year 2022 financial results on March 23, 2023, after market close. A live conference call will begin at 4:30 p.m. ET to discuss these results and other updates. The call can be accessed through registration for dial-in details, or via a live audio webcast on the company’s investor website. ADMA specializes in manufacturing and marketing FDA-approved plasma-derived biologics aimed at treating immunodeficient patients. The company operates its manufacturing plant in Boca Raton, Florida, and has several U.S. patents related to its products.
ADMA Biologics has secured FDA approval for its eighth plasma collection facility located in Hammond, Louisiana, supporting its goal of plasma supply self-sufficiency and ongoing revenue growth. This facility, operational since Q2 2022, can now legally collect human source plasma for plasma-derived biologics. The company aims to have all ten centers FDA-licensed by year-end 2023, further enhancing productivity and profitability. The state-of-the-art center features advanced technology and aims to employ 50 healthcare workers at full capacity.
FAQ
What is the current stock price of Adma Biologics (ADMA)?
What is the market cap of Adma Biologics (ADMA)?
